SPARC seeks US FDA nod to start phase 1 trial of SBO-154 to treat advanced solid tumours: Our Bureau, Mumbai Monday, March 31, 2025, 12:15 Hrs [IST] Sun Pharma Advanced Research C ...

“MUC1 is over-expressed in multiple solid tumors ... of a therapy that shows promise in driving strong, durable anti-tumor immune responses.” U.S. Patent #12,201,685 covers the methods of ...

Versamune MUC1 is a novel MUC1-targeted immunotherapy ... covering methods of using Versamune in combination with immunocytokines to improve anti-tumor immune responses. PDS Biotech is now ...